MAB5412
Anti-Indoleamine 2,3-dioxygenase Antibody, clone 10.1
clone 10.1, Chemicon®, from mouse
Synonyme(s) :
Indoleamine-pyrrole 2,3-dioxygenase
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
10.1, monoclonal
Espèces réactives
human
Réactivité de l'espèce (prédite par homologie)
mouse, rat
Fabricant/nom de marque
Chemicon®
Technique(s)
immunohistochemistry: suitable
western blot: suitable
Isotype
IgG3
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... IDO1(3620)
Description générale
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.
Spécificité
Reacts with Indolamine 2,3-dioxygenase (IDO). Note IDO is usually expressed in response to various stimuli. A good positive control is HeLa cells stimulated with IFN-gamma, {http://www.upstate.com/browse/productdetail.q.ProductID.e.05-840#}.
Immunogène
Amino acids 78-184 of human IDO fused to GST.
Application
Anti-Indoleamine 2, 3-dioxygenase Antibody, clone 10.1 is an antibody against Indoleamine 2 for use in IH & WB.
Immunohistochemistry:
A previous lot of this antibody worked on lightly fixed tissues; Triton X-100 treatment only in the block, not with primary antibody. High temperature antigen retrieval is recommended.
Western blot:
Recognizes a 42-45kDa band in IFN-gamma treated human HeLa cell lines. Mouse IDO runs slightly smaller in blots than human IDO.
Optimal working dilutions must be determined by end user.
A previous lot of this antibody worked on lightly fixed tissues; Triton X-100 treatment only in the block, not with primary antibody. High temperature antigen retrieval is recommended.
Western blot:
Recognizes a 42-45kDa band in IFN-gamma treated human HeLa cell lines. Mouse IDO runs slightly smaller in blots than human IDO.
Optimal working dilutions must be determined by end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Inflammation & Autoimmune Mechanisms
Inflammation & Autoimmune Mechanisms
Qualité
Routinely evaluated by Western Blot on untreated and IFNgamma treated HeLa lysates.
Western blot:
1:500 dilution of this lot detected IDO on 10 μg of untreated and IFN gamma treated HeLa lysates.
Western blot:
1:500 dilution of this lot detected IDO on 10 μg of untreated and IFN gamma treated HeLa lysates.
Description de la cible
42-45kDa
Liaison
Replaces: AB5968
Forme physique
Format: Purified
Protein A purified
Purified mouse monoclonal IgG3 in buffer containing 0.02 M phosphate, 0.25 M NaCl, 0.1% NaN3, pH 7.6.
Stockage et stabilité
Stable for 6 months at 2-8ºC in undiluted aliquots from date of receipt.
Remarque sur l'analyse
Control
IFN-gamma stimulated human peripheral blood lymphocytes, HeLa lysates.
IFN-gamma stimulated human peripheral blood lymphocytes, HeLa lysates.
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Informations légales
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity.
Gupta, NK; Thaker, AI; Kanuri, N; Riehl, TE; Rowley, CW; Stenson, WF; Ciorba, MA
Inflammatory bowel diseases null
Hatem Soliman et al.
Cancer immunology, immunotherapy : CII, 62(5), 829-837 (2013-01-25)
The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancer murine models. Characterizing IDO expression in breast cancer could define which patients receive IDO inhibitors.
Troy A McEachron et al.
Oncoimmunology, 7(12), e1475873-e1475873 (2018-12-14)
Osteosarcomas are aggressive bone tumors for which therapeutic advances have not improved over several decades. Unlike most pediatric tumors, the osteosarcoma genome is remarkably unstable, characterized by numerous copy number alterations and chromosomal structural aberrations. In this study, we asked
Molecular characterization of subcutaneous panniculitis-like T-cell lymphoma reveals upregulation of immunosuppression- and autoimmunity-associated genes.
Maliniemi, P; Hahtola, S; Ovaska, K; Jeskanen, L; Vakeva, L; Jantti, K; Stadler et al.
Orphanet Journal of Rare Diseases null
Antonio Curti et al.
Blood, 109(7), 2871-2877 (2006-12-14)
Indoleamine 2,3-dioxygenase (IDO) is a novel immunosuppressive agent expressed in some subsets of normal and neoplastic cells, including acute myeloid leukemia (AML) cells. Here, we show that IDO expression correlates with increased circulating CD4+CD25+FOXP3+ T cells in patients with AML
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique